

Menggang Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6178111/publications.pdf>

Version: 2024-02-01

132
papers

5,376
citations

117625

34
h-index

91884

69
g-index

135
all docs

135
docs citations

135
times ranked

9171
citing authors

#	ARTICLE	IF	CITATIONS
1	A generalizability score for aggregate causal effect. <i>Biostatistics</i> , 2023, 24, 309-326.	1.5	1
2	A Semiparametric Approach to Model Effect Modification. <i>Journal of the American Statistical Association</i> , 2022, 117, 752-764.	3.1	7
3	Sufficient dimension reduction for populations with structured heterogeneity. <i>Biometrics</i> , 2022, 78, 1626-1638.	1.4	0
4	Tcof1 haploinsufficiency promotes early T cell precursor-like leukemia in NrasQ61R/+ mice. <i>Leukemia</i> , 2022, , .	7.2	0
5	Risk from delayed or missed care and COVID-19 outcomes for older patients with chronic conditions during the pandemic. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 1314-1324.	2.6	13
6	Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>Cureus</i> , 2022, 14, e23783.	0.5	1
7	Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 202-207.	1.3	4
8	Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring. <i>Cancer</i> , 2022, 128, 2892-2897.	4.1	6
9	Impactability Modeling for Reducing Medicare Accountable Care Organization Payments and Hospital Events in High-Need High-Cost Patients: Longitudinal Cohort Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e29420.	4.3	0
10	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3633-3641.	1.6	12
11	Tailored optimal posttreatment surveillance for cancer recurrence. <i>Biometrics</i> , 2021, 77, 942-955.	1.4	0
12	Sample Size Determination for Stratified Phase II Cancer Trials With Monotone Order Constraints. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 425-434.	0.8	1
13	Structure-preserving integrated analysis for risk stratification with application to cancer staging. <i>Biostatistics</i> , 2021, , .	1.5	0
14	Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort. <i>Neurology</i> , 2021, 96, e2500-e2512.	1.1	32
15	One Quarter of Medicare Hospitalizations in Patients with Systemic Lupus Erythematosus Readmitted within Thirty Days. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 477-485.	3.4	8
16	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. <i>Hematological Oncology</i> , 2021, 39, 473-482.	1.7	5
17	Diagnosis-group-specific transitional care program recommendations for 30-day rehospitalization reduction. <i>Annals of Applied Statistics</i> , 2021, 15, .	1.1	1
18	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 1644.	7.1	21

#	ARTICLE	IF	CITATIONS
19	Cox regression with survival-time-dependent missing covariate values. <i>Biometrics</i> , 2020, 76, 460-471.	1.4	3
20	Quantile treatment effect estimation with dimension reduction. <i>Statistical Theory and Related Fields</i> , 2020, 4, 202-213.	0.4	1
21	A practical model for research with learning health systems: Building and implementing effective complex case management. <i>Applied Ergonomics</i> , 2020, 84, 103023.	3.1	9
22	Thirty-Day Re-observation, Chronic Re-observation, and Neighborhood Disadvantage. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2644-2654.	3.0	27
23	Association of Neighborhood-Level Disadvantage With Alzheimer Disease Neuropathology. <i>JAMA Network Open</i> , 2020, 3, e207559.	5.9	92
24	Tailored interventions to reduce hospital admissions for individuals with cerebral palsy. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 889-889.	2.1	1
25	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1797-1806.	1.6	102
26	Fused comparative intervention scoring for heterogeneity of longitudinal intervention effects. <i>Annals of Applied Statistics</i> , 2019, 13, .	1.1	5
27	The importance of health insurance claims data in creating learning health systems: evaluating care for high-need high-cost patients using the National Patient-Centered Clinical Research Network (PCORNet). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 1305-1313.	4.4	10
28	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.	1.2	17
29	Analysis and Design of Clinical Trials Using Additive Hazards Survival Endpoints. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 274-282.	0.8	1
30	Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 662-667.	1.3	15
31	Chemoprotective Effects of Dietary Grape Powder on UVB Radiation-Mediated Skin Carcinogenesis in SKH-1 Hairless Mice. <i>Journal of Investigative Dermatology</i> , 2019, 139, 552-561.	0.7	19
32	Instrumental Variable Based Estimation Under the Semiparametric Accelerated Failure Time Model. <i>Biometrics</i> , 2019, 75, 516-527.	1.4	4
33	Optimal treatment assignment of multiple treatments with analysis of variance decomposition. <i>Statistics and Its Interface</i> , 2019, 12, 355-363.	0.3	0
34	Optimal treatment assignment of multiple treatments with analysis of variance decomposition. <i>Statistics and Its Interface</i> , 2019, 12, 355-363.	0.3	0
35	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , 2018, 73, 751-759.	1.9	99
36	A Computational-Based Approach to Identify Estrogen Receptor α Heterodimer Selective Ligands. <i>Molecular Pharmacology</i> , 2018, 93, 197-207.	2.3	10

#	ARTICLE	IF	CITATIONS
37	The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients. <i>American Journal of Pathology</i> , 2018, 188, 559-573.	3.8	75
38	Risk Prediction for Heterogeneous Populations with Application to Hospital Admission Prediction. <i>Biometrics</i> , 2018, 74, 557-565.	1.4	14
39	Optimal Treatment Assignment to Maximize Expected Outcome with Multiple Treatments. <i>Biometrics</i> , 2018, 74, 506-516.	1.4	6
40	Impact of sufficient dimension reduction in nonparametric estimation of causal effect. <i>Statistical Theory and Related Fields</i> , 2018, 2, 89-95.	0.4	4
41	Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01). <i>Journal of Clinical Oncology</i> , 2018, 36, 975-980.	1.6	23
42	On the effect of electronic patient portal on primary care utilization and appointment adherence. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 84.	3.0	40
43	A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). <i>Annals of Surgical Oncology</i> , 2018, 25, 2587-2595.	1.5	8
44	A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect. <i>Biometrics</i> , 2018, 74, 1292-1300.	1.4	13
45	A General Statistical Framework for Subgroup Identification and Comparative Treatment Scoring. <i>Biometrics</i> , 2017, 73, 1199-1209.	1.4	75
46	Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. <i>Breast Cancer Research</i> , 2017, 19, 9.	5.0	104
47	A statistical framework for pathway and gene identification from integrative analysis. <i>Journal of Multivariate Analysis</i> , 2017, 156, 1-17.	1.0	1
48	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	7.1	219
49	Semiparametric regression on cumulative incidence function with interval-censored competing risks data. <i>Statistics in Medicine</i> , 2017, 36, 3683-3707.	1.6	17
50	A new method to address unmeasured confounding of mortality in observational studies. <i>Learning Health Systems</i> , 2017, 1, e10016.	2.0	2
51	Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1126.	2.2	23
52	Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database. <i>Head and Neck</i> , 2017, 39, 2159-2170.	2.0	13
53	Prognostic implications of human papillomavirus status for patients with non-oro-pharyngeal head and neck squamous cell carcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2341-2350.	2.5	30
54	Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	25

#	ARTICLE	IF	CITATIONS
55	Treatment recommendation and parameter estimation under single-index contrast function. <i>Statistical Theory and Related Fields</i> , 2017, 1, 171-181.	0.4	2
56	Personalised treatment assignment maximising expected benefit with smooth hinge loss. <i>Statistical Theory and Related Fields</i> , 2017, 1, 37-47.	0.4	0
57	HPV impacts survival of stage IVC non-oro-pharyngeal HNSCC cancer patients. <i>Otorhinolaryngology-head and Neck Surgery</i> , 2017, 2, .	0.1	8
58	Joint models for multiple longitudinal processes and time-to-event outcome. <i>Journal of Statistical Computation and Simulation</i> , 2016, 86, 3682-3700.	1.2	14
59	Improving estimation efficiency for semi-competing risks data with partially observed terminal event. <i>Journal of Nonparametric Statistics</i> , 2016, 28, 860-874.	0.9	3
60	Utility of Clinical Breast Examinations in Detecting Localâ€œRegional Breast Events After Breast-Conservation in Women with a Personal History of High-Risk Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3385-3391.	1.5	6
61	Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 985-993.	0.8	67
62	Identification of subgroups with differential treatment effects for longitudinal and multiresponse variables. <i>Statistics in Medicine</i> , 2016, 35, 4837-4855.	1.6	26
63	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1612-1620.	10.7	182
64	Prediction of coronary artery disease risk based on multiple longitudinal biomarkers. <i>Statistics in Medicine</i> , 2016, 35, 1299-1314.	1.6	20
65	Sample size under the additive hazards model. <i>Clinical Trials</i> , 2016, 13, 188-198.	1.6	7
66	Advanced colorectal neoplasia risk stratification by penalized logistic regression. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1677-1691.	1.5	4
67	Prevalence of Human Papillomavirus in Oropharyngeal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 138-146.	2.0	168
68	Regularized outcome weighted subgroup identification for differential treatment effects. <i>Biometrics</i> , 2015, 71, 645-653.	1.4	57
69	Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors. <i>PLoS ONE</i> , 2015, 10, e0128143.	2.5	6
70	Statistical inference for extended or shortened phase II studies based on Simonâ€™s two-stage designs. <i>BMC Medical Research Methodology</i> , 2015, 15, 48.	3.1	10
71	Group Variable Selection via Convex Log-Exp-Sum Penalty with Application to a Breast Cancer Survivor Study. <i>Biometrics</i> , 2015, 71, 53-62.	1.4	7
72	Marginal and Conditional Distribution Estimation from Doubleâ€œsampled Semiâ€œcompeting Risks Data. <i>Scandinavian Journal of Statistics</i> , 2015, 42, 87-103.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Hospice Enrollment, Local Hospice Utilization Patterns, and Rehospitalization in Medicare Patients. <i>Journal of Palliative Medicine</i> , 2015, 18, 601-612.	1.1	15
74	Bayesian approach for flexible modeling of semicompeting risks data. <i>Statistics in Medicine</i> , 2014, 33, 5111-5125.	1.6	12
75	Meta-analysis based variable selection for gene expression data. <i>Biometrics</i> , 2014, 70, 872-880.	1.4	26
76	Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). <i>Journal of Geriatric Oncology</i> , 2014, 5, 230-237.	1.0	4
77	Somatosensory amplification and menopausal symptoms in breast cancer survivors and midlife women. <i>Maturitas</i> , 2014, 78, 51-55.	2.4	10
78	Discussion of "Combining biomarkers to optimize patient treatment recommendations" by Chaeryon Kang, Holly Janes, and Ying Huang. <i>Biometrics</i> , 2014, 70, 716-719.	1.4	0
79	Prevalence of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma in the United States Across Time. <i>Chemical Research in Toxicology</i> , 2014, 27, 462-469.	3.3	80
80	CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis. <i>Cancer Cell</i> , 2014, 25, 21-36.	16.8	215
81	Neighborhood Socioeconomic Disadvantage and 30-Day Rehospitalization. <i>Annals of Internal Medicine</i> , 2014, 161, 765.	3.9	816
82	Paced Respiration for Vasomotor and Other Menopausal Symptoms: A Randomized, Controlled Trial. <i>Journal of General Internal Medicine</i> , 2013, 28, 193-200.	2.6	40
83	Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77. <i>Clinical Lung Cancer</i> , 2013, 14, 224-229.	2.6	12
84	A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. <i>Investigational New Drugs</i> , 2013, 31, 1307-1310.	2.6	27
85	Plasma choline-containing phospholipids: potential biomarkers for colorectal cancer progression. <i>Metabolomics</i> , 2013, 9, 202-212.	3.0	19
86	A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 86-97.	1.9	20
87	Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 175-181.	1.9	78
88	Stat3 Downstream Gene Product Chitinase 3-Like 1 Is a Potential Biomarker of Inflammation-induced Lung Cancer in Multiple Mouse Lung Tumor Models and Humans. <i>PLoS ONE</i> , 2013, 8, e61984.	2.5	10
89	Strategies Used and Data Obtained During Treatment Fidelity Monitoring. <i>Nursing Research</i> , 2013, 62, 59-65.	1.7	12
90	Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts. <i>Clinical Cancer Research</i> , 2013, 19, 855-864.	7.0	85

#	ARTICLE	IF	CITATIONS
91	Testing and Sample Size for Polygonal One-Sided Hypotheses on Bivariate Binary Outcomes. <i>Statistics in Biopharmaceutical Research</i> , 2013, 5, 1-17.	0.8	1
92	Risk factors, pathophysiology, and treatment of hot flashes in cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 167-192.	329.8	38
93	A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1425-1429.	1.1	17
94	Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 4416-4426.	1.6	197
95	Perceived Control and Hot Flashes in Treatment-Seeking Breast Cancer Survivors and Menopausal Women. <i>Cancer Nursing</i> , 2012, 35, 195-202.	1.5	10
96	Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group G106-101. <i>Oncologist</i> , 2012, 17, 13-e23.	3.7	66
97	Evaluating the Role of Serotonin on Neuropsychological Function After Breast Cancer Using Acute Tryptophan Depletion. <i>Biological Research for Nursing</i> , 2012, 14, 5-15.	1.9	3
98	Genetic disruption of the PI3K regulatory subunits, p85 \hat{A} , p55 \hat{A} , and p50 \hat{A} , normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. <i>Haematologica</i> , 2012, 97, 1042-1047.	3.5	17
99	Advanced cognitive training for breast cancer survivors: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 799-809.	2.5	175
100	Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1218-1224.	10.7	195
101	Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2012, 38, 919-925.	7.7	53
102	Designing cost-efficient randomized trials by using flexible recruitment strategies. <i>BMC Medical Research Methodology</i> , 2012, 12, 106.	3.1	1
103	Prior event rate ratio adjustment: numerical studies of a statistical method to address unrecognized confounding in observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 60-68.	1.9	28
104	Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group G103-53. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 25-32.	2.3	16
105	The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Malignant Disease in Vivo and Co-Localizes with Nuclear Phospho-STAT5 in FLT3-ITD-Expressing Leukemic Cells.. <i>Blood</i> , 2012, 120, 2420-2420.	1.4	0
106	A Phase II Study of Gemcitabine in Combination With Radiation Therapy in Patients With Localized, Unresectable, Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 460-465.	1.3	60
107	Buckley \hat{A} James Type Estimator for Censored Data with Covariates Missing by Design. <i>Scandinavian Journal of Statistics</i> , 2011, 38, 252-267.	1.4	5
108	Ethanol-Induced Alterations in Fatty Acid-Related Lipids in Serum and Tissues in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 229-234.	2.4	46

#	ARTICLE	IF	CITATIONS
109	Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group. <i>Journal of Thoracic Oncology</i> , 2010, 5, 2008-2011.	1.1	46
110	Regression Calibration in Semiparametric Accelerated Failure Time Models. <i>Biometrics</i> , 2010, 66, 405-414.	1.4	11
111	Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 260-265.	1.0	46
112	Costimulatory Effects of Interleukin-18 (IL-18) on Human Natural Killer (NK) Cells Activated through Fc Receptors for Immunoglobulin (IgG). <i>Blood</i> , 2010, 116, 2780-2780.	1.4	0
113	Increased c-Jun Expression and Reduced GATA2 Expression Promote Aberrant Monocytic Differentiation Induced by Activating <i>PTPN11</i> Mutants. <i>Molecular and Cellular Biology</i> , 2009, 29, 4376-4393.	2.3	28
114	Ras Dependent Paracrine Secretion of Osteopontin by <i>Nf1</i> + Osteoblasts Promote Osteoclast Activation in a Neurofibromatosis Type I Murine Model. <i>Pediatric Research</i> , 2009, 65, 613-618.	2.3	24
115	A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. <i>Investigational New Drugs</i> , 2009, 27, 565-570.	2.6	23
116	NF- κ B inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. <i>Cancer Letters</i> , 2009, 278, 145-155.	7.2	67
117	Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. <i>Menopause</i> , 2009, 16, 644-652.	2.0	11
118	Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study. <i>Journal of Thoracic Oncology</i> , 2009, 4, 93-96.	1.1	29
119	Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1420-1424.	1.1	18
120	<i>Nf1</i> -Dependent Tumors Require a Microenvironment Containing <i>Nf1</i> + and <i>c-kit</i> -Dependent Bone Marrow. <i>Cell</i> , 2008, 135, 437-448.	28.9	325
121	Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal Survival-Cure Model. <i>Journal of the American Statistical Association</i> , 2008, 103, 178-187.	3.1	74
122	A Bayesian Meta-Analysis on Published Sample Mean and Variance Pharmacokinetic Data with Application to Drug-Drug Interaction Prediction. <i>Journal of Biopharmaceutical Statistics</i> , 2008, 18, 1063-1083.	0.8	10
123	Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group. <i>Journal of Thoracic Oncology</i> , 2008, 3, 374-379.	1.1	20
124	A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naïve Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 1131-1137.	7.0	20
125	Drug-drug interaction prediction: a Bayesian meta-analysis approach. <i>Statistics in Medicine</i> , 2007, 26, 3700-3721.	1.6	19
126	Buckley-James-type of estimators under the classical case cohort design. <i>Annals of the Institute of Statistical Mathematics</i> , 2007, 59, 675-695.	0.8	4

#	ARTICLE	IF	CITATIONS
127	A hybrid Newton-type method for censored survival data using double weights in linear models. <i>Lifetime Data Analysis</i> , 2006, 12, 345-364.	0.9	12
128	Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. <i>Human Molecular Genetics</i> , 2006, 15, 2837-2845.	2.9	89
129	Censored linear regression for case-cohort studies. <i>Biometrika</i> , 2006, 93, 747-762.	2.4	33
130	Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. <i>Blood</i> , 2005, 105, 3737-3742.	1.4	147
131	Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. <i>Urology</i> , 2002, 60, 276-280.	1.0	38
132	Bias and Efficiency Loss Due to Categorizing an Explanatory Variable. <i>Journal of Multivariate Analysis</i> , 2002, 83, 248-263.	1.0	63